Kubota Vision

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Kubota Vision sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials none currently recruiting 16 completed early-phase tilt top decile by trial count

Kubota Vision: 16 sponsored US clinical trials, none currently recruiting.

Kubota Vision sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Keratoconjunctivitis Sicca, with 1 trials.

Top-decile sponsor footprint

Kubota Vision ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

16 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

16 total, page 1 of 1

COMPLETED NA

Kubota Glass Parameter Refinement Study

NCT06085430

COMPLETED NA

Projected Peripheral Defocus Using a Wearable Device

NCT04415684

COMPLETED NA

Effects of Projected Peripheral Defocus on Ocular Biometrics

NCT04388020

COMPLETED

Study Evaluating Retinal Health Monitoring System Visual Acuity Module.

NCT04169802

COMPLETED Phase 3

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665

COMPLETED Phase 2

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

NCT03033108

COMPLETED Phase 2

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400

COMPLETED Phase 1

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT02130531

COMPLETED Phase 2

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866

COMPLETED Phase 3

Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

NCT01632137

COMPLETED Phase 1

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188

COMPLETED Phase 2

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

NCT01057147

COMPLETED Phase 2

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

NCT01027013

COMPLETED Phase 2

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

NCT01002950

COMPLETED Phase 1

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

NCT00942240

COMPLETED Phase 1

Safety and Tolerability of ACU-4429

NCT00703183

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 6
Phase 3 2

How the Kubota Vision early-phase archive is shaped

16 indexed studies, none listed as recruiting (0% open); 16 completed (100%).

Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Keratoconjunctivitis Sicca (1 trial), 6 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Kubota Vision: archived-pipeline peers nationwide

Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Kubota Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15% Total trials Recruiting share Kubota VisionAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Kubota Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kubota Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Kubota Vision page

16 registered trials is a research-attention snapshot, not an endorsement of Kubota Vision or any single study.

  • None of Kubota Vision's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Keratoconjunctivitis Sicca is the condition Kubota Vision studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Keratoconjunctivitis Sicca trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kubota Vision pipeline card: 16 registered trials from official public datasets.Report a data error.